Intended for overactive bladder to manage urinary urgency and support bladder control.
Mechanism of Action
Solifenacin is a competitive muscarinic receptor antagonist. It specifically targets M3 receptors in the bladder wall, inhibiting detrusor muscle contraction to increase bladder capacity and reduce the frequency of urgency.
Route of Administration
Oral
Onset Time
4 weeks
Duration
24 hours
Contraindications
Urinary retention, Gastric retention, Uncontrolled narrow-angle glaucoma, Severe hepatic impairment
Severe Adverse Events
Angioedema, Qt prolongation, Severe confusion — requires immediate medical attention
Common Side Effects
Dry mouth, Constipation, Blurred vision
Uncommon Side Effects
Nausea, Dyspepsia, Urinary tract infection
Drug Interactions
Alcohol, Ketoconazole, Ritonavir, Erythromycin
Pregnancy Safety Warnings
FDA Category C: Use only if clearly needed. Breastfeeding: Not known if excreted in milk.
Age Restrictions
Safety and efficacy established in pediatric patients two years and older.
Information related to Solifenacin is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
